JP2021528391A - Ｊａｋファミリーのキナーゼの低分子阻害物質 - Google Patents

Ｊａｋファミリーのキナーゼの低分子阻害物質 Download PDF

Info

Publication number
JP2021528391A
JP2021528391A JP2020569049A JP2020569049A JP2021528391A JP 2021528391 A JP2021528391 A JP 2021528391A JP 2020569049 A JP2020569049 A JP 2020569049A JP 2020569049 A JP2020569049 A JP 2020569049A JP 2021528391 A JP2021528391 A JP 2021528391A
Authority
JP
Japan
Prior art keywords
compound
suspension
diffractogram
jak
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020569049A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528391A5 (https=
JPWO2019239387A5 (https=
Inventor
ジェイ． クラフチュク，ポール
フェルナンデス，フィリップ
エス． ティチェナー，マーク
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2021528391A publication Critical patent/JP2021528391A/ja
Publication of JP2021528391A5 publication Critical patent/JP2021528391A5/ja
Publication of JPWO2019239387A5 publication Critical patent/JPWO2019239387A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
JP2020569049A 2018-06-15 2019-06-14 Ｊａｋファミリーのキナーゼの低分子阻害物質 Pending JP2021528391A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862685737P 2018-06-15 2018-06-15
US62/685,737 2018-06-15
US201962846290P 2019-05-10 2019-05-10
US62/846,290 2019-05-10
PCT/IB2019/055005 WO2019239387A1 (en) 2018-06-15 2019-06-14 Small molecule inhibitors of the jak family of kinases

Publications (3)

Publication Number Publication Date
JP2021528391A true JP2021528391A (ja) 2021-10-21
JP2021528391A5 JP2021528391A5 (https=) 2022-04-11
JPWO2019239387A5 JPWO2019239387A5 (https=) 2022-04-11

Family

ID=67766195

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020569049A Pending JP2021528391A (ja) 2018-06-15 2019-06-14 Ｊａｋファミリーのキナーゼの低分子阻害物質

Country Status (23)

Country Link
US (3) US20200017498A1 (https=)
EP (1) EP3807277A1 (https=)
JP (1) JP2021528391A (https=)
KR (1) KR102768284B1 (https=)
CN (1) CN112313233A (https=)
AU (1) AU2019286641A1 (https=)
BR (1) BR112020024744A2 (https=)
CA (1) CA3101438A1 (https=)
CL (1) CL2020003227A1 (https=)
CO (1) CO2020015396A2 (https=)
CR (1) CR20200603A (https=)
EC (1) ECSP20080817A (https=)
IL (1) IL279314A (https=)
JO (1) JOP20200311A1 (https=)
MA (1) MA52900A (https=)
MX (1) MX2020013688A (https=)
NI (1) NI202000100A (https=)
PE (1) PE20212113A1 (https=)
PH (1) PH12020551984A1 (https=)
SG (1) SG11202011691PA (https=)
TW (1) TW202016110A (https=)
UY (1) UY38262A (https=)
WO (1) WO2019239387A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3555097T (lt) 2016-12-16 2022-08-25 Janssen Pharmaceutica Nv Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
BR112023018286A2 (pt) * 2021-03-11 2023-10-31 Janssen Pharmaceutica Nv Lorpucitinib para uso no tratamento de distúrbios mediados por jak
CN113292561A (zh) * 2021-05-22 2021-08-24 中国药科大学 一种二吡咯并吡啶结构的化合物、制备方法和医药用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
JP2013517220A (ja) * 2010-01-12 2013-05-16 エフ．ホフマン−ラ ロシュ アーゲー 三環式複素環式化合物、その組成物、及び使用の方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
UA67844C2 (uk) 1999-04-23 2004-07-15 Смітклайн Бічам Плс Поліморф 5-[4-[2-(n-метил-n-(2-піридил)аміно)етокси]бензил]тіазолідин-2,4-діону солі малеїнової кислоти
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
MXPA04011865A (es) 2002-05-31 2005-03-31 Schering Corp Polimorfos inhibidores de xantina fosfodiesterasa v.
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
EP1902029B2 (en) 2005-07-01 2022-02-16 Wyeth LLC Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
WO2007007919A2 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
JP5748659B2 (ja) 2008-06-10 2015-07-15 アッヴィ・インコーポレイテッド 新規な三環式化合物
JP5567137B2 (ja) 2009-09-03 2014-08-06 ブリストル−マイヤーズ スクイブ カンパニー Ｊａｋ２阻害剤、ならびに骨髄増殖性疾患および癌の治療のためのそれらの使用
KR20120102724A (ko) 2009-12-01 2012-09-18 아보트 러보러터리즈 신규한 트리사이클릭 화합물
PE20121336A1 (es) 2009-12-01 2012-11-03 Abbvie Inc Nuevos compuestos triciclicos
EP2534258B1 (en) 2010-02-10 2017-09-20 Genon Biotechnologies OY Dual activity kinase domains and uses thereof
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
JP6248948B2 (ja) 2013-02-08 2017-12-20 日産化学工業株式会社 ３環性ピロロピリジン化合物及びｊａｋ阻害剤
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
WO2015174376A1 (ja) 2014-05-14 2015-11-19 日産化学工業株式会社 ３環性化合物及びｊａｋ阻害剤
JP6692836B2 (ja) 2015-05-28 2020-05-13 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物
EP3371332A4 (en) 2015-11-04 2019-04-03 Mayo Foundation for Medical Education and Research METHOD AND MATERIALS FOR TREATING AUTOIMMUNE DISEASES
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
TWI735681B (zh) 2016-10-24 2021-08-11 瑞典商阿斯特捷利康公司 化合物
EP3555064B9 (en) 2016-12-16 2023-03-01 Pfizer Inc. Glp-1 receptor agonists and uses thereof
CA3045224A1 (en) 2016-12-16 2018-06-21 Basf Se Pesticidal compounds
LT3555097T (lt) 2016-12-16 2022-08-25 Janssen Pharmaceutica Nv Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai
KR102276022B1 (ko) 2016-12-16 2021-07-13 일라이 릴리 앤드 캄파니 돌연변이체 idh1 및 idh2 억제제로서의 7-페닐에틸아미노-4h-피리미도[4,5-d][1,3]옥사진-2-온 화합물
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
EP3528645A1 (en) 2016-12-16 2019-08-28 Société des Produits Nestlé S.A. Oligosaccharides for flavour generation
PL3568396T3 (pl) 2017-01-11 2021-05-31 Leo Pharma A/S Nowe pochodne aminoimidazopirydyny jako inhibitory kinaz janusowych i ich zastosowanie farmaceutyczne
PT3494116T (pt) 2017-01-30 2020-01-28 Astrazeneca Ab Moduladores de recetores de estrogénio
WO2018195397A2 (en) 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2020216936A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013517220A (ja) * 2010-01-12 2013-05-16 エフ．ホフマン−ラ ロシュ アーゲー 三環式複素環式化合物、その組成物、及び使用の方法
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases

Also Published As

Publication number Publication date
US20200017498A1 (en) 2020-01-16
US11066406B2 (en) 2021-07-20
EP3807277A1 (en) 2021-04-21
US20210340144A1 (en) 2021-11-04
CR20200603A (es) 2021-01-20
NI202000100A (es) 2021-06-30
BR112020024744A2 (pt) 2021-03-23
KR20210021342A (ko) 2021-02-25
PH12020551984A1 (en) 2021-08-02
UY38262A (es) 2019-12-31
US20200165250A1 (en) 2020-05-28
IL279314A (en) 2021-01-31
WO2019239387A1 (en) 2019-12-19
JOP20200311A1 (ar) 2020-11-30
MA52900A (fr) 2021-04-21
KR102768284B1 (ko) 2025-02-13
ECSP20080817A (es) 2021-01-29
CL2020003227A1 (es) 2021-05-14
TW202016110A (zh) 2020-05-01
CA3101438A1 (en) 2019-12-19
PE20212113A1 (es) 2021-11-04
MX2020013688A (es) 2021-02-26
CO2020015396A2 (es) 2021-03-08
US11787807B2 (en) 2023-10-17
AU2019286641A1 (en) 2020-12-10
SG11202011691PA (en) 2020-12-30
CN112313233A (zh) 2021-02-02

Similar Documents

Publication Publication Date Title
JP7493068B2 (ja) Ｊａｋファミリーのキナーゼの低分子阻害物質
JP2021528391A (ja) Ｊａｋファミリーのキナーゼの低分子阻害物質
CA3046965C (en) Small molecule inhibitors of the jak family of kinases
HK40008834B (zh) Jak家族激酶的小分子抑制剂
EA037347B1 (ru) Низкомолекулярные ингибиторы киназ семейства jak
HK40014753B (en) Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases
HK40014753A (en) Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220401

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231107